rethinkTHC Search
Menu
Study breakdown

Could Ozempic-Type Drugs Help Treat Addiction? What Clinical Trials Are Testing

Systematic ReviewModerate evidence
The takeaway

Thirty-three clinical trials are testing GLP-1 receptor agonists like semaglutide for substance use disorders, mostly focused on alcohol and tobacco, with zero trials targeting cannabis.

Addiction researchers, people interested in GLP-1 drugs, and anyone following developments in substance use disorder treatment.

33 trials for addiction; 0 for cannabis

What the researchers found

A systematic review of ClinicalTrials.gov found 33 trials testing GLP-1 receptor agonists for substance use disorders: alcohol (n=15), nicotine/tobacco (n=9), cocaine (n=4), opioid (n=4), and methamphetamine (n=1). No trials are investigating cannabis use disorder. Semaglutide was the most studied agent (n=15).

Why it matters

The explosion of interest in GLP-1 drugs for addiction reflects growing evidence that the brain's appetite and reward circuits overlap. The complete absence of cannabis-specific trials is notable given that no FDA-approved treatment for cannabis use disorder exists.

The numbers in context

192 records screened, 33 met criteria. Agents: semaglutide (15), exenatide (8), tirzepatide (6), liraglutide (2), dulaglutide (1), pemvidutide (1). Zero trials for cannabis use disorder.

How the study worked

Systematic search of ClinicalTrials.gov from inception to July 2025, identifying trials using GLP-1 receptor agonists as interventions for substance use disorders with substance use outcomes.

What this study cannot tell us

Only registered trials were included; results are not yet available for most. The review captured trial design and registration, not efficacy outcomes. Selection bias in which substances receive research attention.

How to read the evidence

Systematic review of registered clinical trials, but most trials are ongoing and results are not yet available.

When this study was published

2026 review with search through July 2025.

The bigger picture

GLP-1 drugs are already transforming obesity and diabetes treatment. If they prove effective for substance use disorders, it would represent a paradigm shift in addiction medicine. However, most trials use older agents, and standardized endpoints are lacking.

Questions still open

  • Why are there no GLP-1 trials for cannabis use disorder despite having no FDA-approved treatments? Will next-generation GLP-1 drugs like tirzepatide show stronger effects than older agents?

Common questions

Can Ozempic treat drug addiction?
It is being tested. Thirty-three clinical trials are investigating GLP-1 drugs like semaglutide for various addictions, but results are mostly not yet available.
Why is there no trial for cannabis addiction?
The review found this gap without explanation. It is notable because cannabis use disorder has no FDA-approved pharmacotherapy, making it a prime candidate for new treatment approaches.

Read the original research

Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov.

Addictive behaviors reports, 23, 100671

Citation

Patil, Shruti; Jha, Nandini; Jha, Manish K. (2026). Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov.. Addictive behaviors reports, 23, 100671. https://doi.org/10.1016/j.abrep.2026.100671

Explore the wider topic